Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (41-50 of 298) with videos related to

Pageof 30
Sort By:
Current Problems in Dermatology|August 28, 2009
Topical treatment of psoriasisQurat Ul Ain Kamili, Alan Menter
JAMA Dermatology|April 11, 2014
Polymorphic plaques involving the face and extremitiesDaniel Zaghi, Allison Readinger, Alan Menter
Arthritis|December 5, 2012
Psoriatic arthritis: an updatePeter Lloyd, Caitriona Ryan, Alan Menter
Journal of the American Academy of Dermatology|January 17, 2015
Reply to: "Review of drug-related causes of oculocutaneous disease"Jonathan E Mayer, M Alan Menter
Therapeutic Advances in Chronic Disease|January 19, 2018
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasisJillian Frieder, Dario Kivelevitch, Alan Menter
Proceedings (Baylor University. Medical Center)|December 8, 2005
Vesicular eruption including the mouthJennifer Clay Cather, M Alan Menter
Expert Opinion on Investigational Drugs|August 21, 2015
An overview of developing TNF-α targeted therapy for the treatment of psoriasisMolly Campa, Caitriona Ryan, Alan Menter
Journal of Drugs in Dermatology : JDD|February 3, 2010
Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapyQurat ul Ain Kamili, Alan Menter
Expert Opinion on Drug Safety|January 18, 2020
How can we manage the safety concerns associated with the increase in biologics for psoriasis?Annika Silfvast-Kaiser, Martin Alan Menter
Immunotherapy|September 8, 2017
A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasisOmid Roostaeyan, Dario Kivelevitch, Alan Menter
Pageof 30

Showing results (41-50 of 298) with videos related to

Sort By:
Pageof 30
Current Problems in Dermatology|August 28, 2009
Topical treatment of psoriasisQurat Ul Ain Kamili, Alan Menter
JAMA Dermatology|April 11, 2014
Polymorphic plaques involving the face and extremitiesDaniel Zaghi, Allison Readinger, Alan Menter
Arthritis|December 5, 2012
Psoriatic arthritis: an updatePeter Lloyd, Caitriona Ryan, Alan Menter
Journal of the American Academy of Dermatology|January 17, 2015
Reply to: "Review of drug-related causes of oculocutaneous disease"Jonathan E Mayer, M Alan Menter
Therapeutic Advances in Chronic Disease|January 19, 2018
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasisJillian Frieder, Dario Kivelevitch, Alan Menter
Proceedings (Baylor University. Medical Center)|December 8, 2005
Vesicular eruption including the mouthJennifer Clay Cather, M Alan Menter
Expert Opinion on Investigational Drugs|August 21, 2015
An overview of developing TNF-α targeted therapy for the treatment of psoriasisMolly Campa, Caitriona Ryan, Alan Menter
Journal of Drugs in Dermatology : JDD|February 3, 2010
Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapyQurat ul Ain Kamili, Alan Menter
Expert Opinion on Drug Safety|January 18, 2020
How can we manage the safety concerns associated with the increase in biologics for psoriasis?Annika Silfvast-Kaiser, Martin Alan Menter
Immunotherapy|September 8, 2017
A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasisOmid Roostaeyan, Dario Kivelevitch, Alan Menter
Pageof 30